Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer.
Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer.
复制标题
DOI：
10.1002/cam4.1443
复制
发表时间：
2018-05
期刊：
影响因子：
4
通讯作者：
Shigematsu N
中科院分区：
文献类型：
--
作者：
Nishimura S;Ohashi T;Momma T;Sakayori M;Eriguchi T;Tanaka T;Yamashita S;Kosaka T;Oya M;Shigematsu N
已将局部前列腺癌放疗后的前列腺特异性抗原最低值（nPSA）作为预测因素进行了研究。然而，nPSA通常需要数年时间，限制了其临床应用。我们研究了低剂量率前列腺近距离放射治疗（LDR-PB）或外照射放疗（EBRT）后12个月内nPSA（nPSA 12）对治疗结局的意义。2006年至2014年，663例前列腺癌患者在两家机构接受了LDR-PB或EBRT治疗。474例男性接受LDR-PB，189例男性接受EBRT，未接受雄激素剥夺治疗。采用Kaplan-Meier法进行无生化失败（BF）生存期（BFFS）和无远处转移（DM）生存期（DMFS）分析，并进行多变量考克斯回归分析。中位随访时间为61.3个月。LDR-PB和EBRT队列的中位nPSA 12分别为0.7和1.0 ng/mL。nPSA 12 ≤ 0.7 ng/mL的LDR-PB患者的7年BFFS和DMFS率分别为99.1%和99.5%;当nPSA 12>0.7 ng/mL时，分别为90.2%和94.8%。在nPSA 12 ≤ 1.0 ng/mL的EBRT患者中，BFFS和DMFS的发生率分别为85.4%和98.5%，当nPSA 12>1.0 ng/mL时，BFFS和DMFS的发生率分别为67.1%和87.2%。在两个队列中，nPSA 12是BF和DM的独立预测因子（LDR-PB，分别为P = 0.004和0.020; EBRT，分别为P = 0.005和0.041）。LDR-PB或EBRT后的nPSA 12与前列腺癌的治疗结局显著相关。较高的nPSA 12可识别可能从挽救治疗中获益的复发高风险患者。
Prostate‐specific antigen nadir (nPSA) after radiotherapy for localized prostate cancer has been investigated as a predictor. However, nPSA usually requires several years, limiting its clinical utility. We investigated the significance of nPSA within 12 months (nPSA12) after low‐dose‐rate prostate brachytherapy (LDR‐PB) or external beam radiotherapy (EBRT) on treatment outcomes. Between 2006 and 2014, 663 patients with prostate cancer were treated with LDR‐PB or EBRT at two institutions. Four hundred and seventy‐four men received LDR‐PB and 189 men received EBRT, without androgen deprivation therapy. The Kaplan–Meier method was used for biochemical failure (BF)‐free survival (BFFS) and distant metastasis (DM)‐free survival (DMFS) analyses, and multivariable Cox regression analysis was performed. The median follow‐up was 61.3 months. The median nPSA12 in the LDR‐PB and EBRT cohorts was 0.7 and 1.0 ng/mL, respectively. The 7‐year BFFS and DMFS rates in LDR‐PB patients with nPSA12 ≤ 0.7 ng/mL were 99.1% and 99.5%, respectively; when nPSA12 was >0.7 ng/mL, they were 90.2% and 94.8%, respectively. In EBRT patients with nPSA12 ≤ 1.0 ng/mL, BFFS and DMFS rates were 85.4% and 98.5%, respectively; when nPSA12 was >1.0 ng/mL, they were 67.1% and 87.2%, respectively. nPSA12 was an independent predictor of BF and DM in both cohorts (LDR‐PB, P = 0.004 and 0.020, respectively; EBRT, P = 0.005 and 0.041, respectively). The nPSA12 after LDR‐PB or EBRT is significantly associated with treatment outcomes of prostate cancer. Higher nPSA12 may identify patients at high risk of relapse who might benefit from salvage treatment.
登录
查看更多内容
影响因子：
6.6
作者：
ROGERS, E;OHORI, M;SCARDINO, PT
通讯作者：
SCARDINO, PT
影响因子：
23.4
作者：
Chade, Daher C.;Shariat, Shahrokh F.;Eastham, James A.
通讯作者：
Eastham, James A.
DOI：
10.1016/j.ijrobp.2013.10.010
发表时间：
2014-01-01
影响因子：
7
作者：
Lo, Andrea C.;Morris, W. James;Spadinger, Ingrid
通讯作者：
Spadinger, Ingrid
影响因子：
5.7
作者：
Wojcieszek, Piotr;Szlag, Marta;Fijalkowski, Marek
通讯作者：
Fijalkowski, Marek
影响因子：
5.7
作者：
Peters, Max;Maenhout, Metha;van Vulpen, Marco
通讯作者：
van Vulpen, Marco